The CanISleepinMS Study: Effect of Cannabidiol (CBD) on Sleep Quality in Patients With Multiple Sclerosis

The investigators conducted a series of 16 aggregated randomized, placebo-controlled N-of-1 trials to investigate the effect of purified cannabidiol (CBD) oil on nocturnal sleep quality in patients with multiple sclerosis. Each participant completed four treatment periods: two with CBD (300 mg daily) and two with placebo. The primary outcome is the insomnia severity index (ISI). Secondary outcomes included a sleep-wake diary and scores on the Checklist Individual Strength Fatigue subscale (CIS-F), Fatigue Severity Scale (FSS), and Epworth Sleepiness Scale (ESS).